These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27286929)

  • 1. Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor.
    Thompson GL; Lane JR; Coudrat T; Sexton PM; Christopoulos A; Canals M
    Biochem Pharmacol; 2016 Aug; 113():70-87. PubMed ID: 27286929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor.
    Thompson GL; Lane JR; Coudrat T; Sexton PM; Christopoulos A; Canals M
    Mol Pharmacol; 2015 Aug; 88(2):335-46. PubMed ID: 26013541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endomorphin-1/2 and dynorphin-B peptides display biased agonism at the mu opioid receptor.
    LaVigne J; Keresztes A; Chiem D; Streicher JM
    Pharmacol Rep; 2020 Apr; 72(2):465-471. PubMed ID: 32112361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists.
    Winpenny D; Clark M; Cawkill D
    Br J Pharmacol; 2016 Apr; 173(8):1393-403. PubMed ID: 26791140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics?
    Madariaga-Mazón A; Marmolejo-Valencia AF; Li Y; Toll L; Houghten RA; Martinez-Mayorga K
    Drug Discov Today; 2017 Nov; 22(11):1719-1729. PubMed ID: 28743488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encoding mu-opioid receptor biased agonism with interaction fingerprints.
    Hernández-Alvarado RB; Madariaga-Mazón A; Cosme-Vela F; Marmolejo-Valencia AF; Nefzi A; Martinez-Mayorga K
    J Comput Aided Mol Des; 2021 Nov; 35(11):1081-1093. PubMed ID: 34713377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics.
    Siuda ER; Carr R; Rominger DH; Violin JD
    Curr Opin Pharmacol; 2017 Feb; 32():77-84. PubMed ID: 27936408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel GPCR paradigms at the μ-opioid receptor.
    Thompson GL; Kelly E; Christopoulos A; Canals M
    Br J Pharmacol; 2015 Jan; 172(2):287-96. PubMed ID: 24460711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation.
    Piekielna-Ciesielska J; Artali R; Azzam AAH; Lambert DG; Kluczyk A; Gentilucci L; Janecka A
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33375124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and ligand bias at the μ-opioid receptor.
    Kelly E
    Br J Pharmacol; 2013 Aug; 169(7):1430-46. PubMed ID: 23646826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hot topics in opioid pharmacology: mixed and biased opioids.
    Azzam AAH; McDonald J; Lambert DG
    Br J Anaesth; 2019 Jun; 122(6):e136-e145. PubMed ID: 31010646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclopeptide Dmt-[D-Lys-p-CF
    Piekielna-Ciesielska J; Ferrari F; Calo' G; Janecka A
    Peptides; 2018 Mar; 101():227-233. PubMed ID: 29196181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro.
    Knapman A; Santiago M; Connor M
    Br J Pharmacol; 2014 Sep; 171(18):4273-88. PubMed ID: 24846673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
    Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
    Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular insights into the biased signaling mechanism of the μ-opioid receptor.
    Cong X; Maurel D; Déméné H; Vasiliauskaité-Brooks I; Hagelberger J; Peysson F; Saint-Paul J; Golebiowski J; Granier S; Sounier R
    Mol Cell; 2021 Oct; 81(20):4165-4175.e6. PubMed ID: 34433090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Biased View of
    Conibear AE; Kelly E
    Mol Pharmacol; 2019 Nov; 96(5):542-549. PubMed ID: 31175184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias.
    Yang Y; Wang Y; Zuo A; Li C; Wang W; Jiang W; Zhang X; Che X; Zhang Y; Wu W; Cen X; Wang H; Tian J
    Eur J Med Chem; 2022 Jan; 228():113986. PubMed ID: 34802839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Effects of Ligand Bias on Primate Mu Opioid Receptor Downstream Signaling.
    Zhang X; Hutchins SD; Blough BE; Vallender EJ
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32503269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling diversity of mu- and delta- opioid receptor ligands: Re-evaluating the benefits of β-arrestin/G protein signaling bias.
    Pineyro G; Nagi K
    Cell Signal; 2021 Apr; 80():109906. PubMed ID: 33383156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics.
    Pedersen MF; Wróbel TM; Märcher-Rørsted E; Pedersen DS; Møller TC; Gabriele F; Pedersen H; Matosiuk D; Foster SR; Bouvier M; Bräuner-Osborne H
    Neuropharmacology; 2020 Apr; 166():107718. PubMed ID: 31351108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.